Safety and Effectiveness of Nitazoxanide for the Treatment of Cryptosporidiosis in AIDS Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to see if it is safe and effective to treat cryptosporidiosis in AIDS patients with nitazoxanide.
| Condition | Intervention | Phase |
|---|---|---|
|
Cryptosporidiosis HIV Infections |
Drug: Nitazoxanide |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety Study Primary Purpose: Treatment |
| Official Title: | Open Label, Multi-Center Evaluation of Nitazoxanide for the Treatment of Cryptosporidiosis in Subjects With AIDS in the United States |
| Estimated Enrollment: | 30 |
| Study Start Date: | February 2000 |
Patients take nitazoxanide daily for 8 weeks with a dose escalation after the first 4 weeks. Patients return to the hospital for examinations every 2 weeks during the 8-week treatment period and 6-week follow-up. Nitazoxanide therapy is discontinued in patients showing a complete clinical and parasitologic response (therapeutic cure) after 8 weeks of treatment and in patients showing a therapeutic cure at two consecutive visits (Weeks 2 and 4 or Weeks 4 and 6). These patients undergo a physical examination including stool analysis for Cryptosporidium parvum oocysts and routine laboratory tests at Weeks 2, 4, and 6 after completion of nitazoxanide therapy. Patients who do not show a complete clinical and parasitologic response (therapeutic failure) after 8 weeks of treatment are allowed to remain on nitazoxanide therapy through the Open Label Compassionate Use of Nitazoxanide in Treatment of Cryptosporidiosis in AIDS Patients (UMD-95-009) protocol.
Eligibility| Ages Eligible for Study: | 13 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria
Patients may be eligible for this study if they:
- Are HIV-positive.
- Have a CD4 cell count of 50 cells/mm3 or less.
- Have evidence of cryptosporidium infection in their stool sample within 10 days of study entry.
- Have watery stools at least three times a day at least 5 days a week for 21 days prior to enrollment.
- Are able to take medications by mouth.
- Are at least 13 years old (consent of parent or guardian required if under 18).
- Agree to use an effective method of birth control (such as condoms) during the study.
Exclusion Criteria
Patients will not be eligible if they:
- Have certain diseases or infections of the intestines.
- Have ever taken nitazoxanide.
- Have taken certain experimental drugs within 14 days of enrollment.
- Will need to take certain other medications during the study such as paromomycin, azithromycin, and clarithromycin.
- Have started a new anti-HIV therapy within 4 weeks of study entry or plan on starting one during the study.
- Are pregnant or breast-feeding.
Contacts and Locations More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00004986 History of Changes |
| Other Study ID Numbers: | 253C, RM-NTZ-99-003 |
| Study First Received: | March 16, 2000 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
AIDS-Related Opportunistic Infections Cryptosporidiosis Drug Evaluation |
Antiprotozoal Agents Treatment Failure nitazoxanide |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Cryptosporidiosis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Intestinal Diseases, Parasitic Parasitic Diseases |
Protozoan Infections, Animal Parasitic Diseases, Animal Coccidiosis Protozoan Infections Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases Antiprotozoal Agents Nitazoxanide Antiparasitic Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions |
ClinicalTrials.gov processed this record on May 23, 2013